Alterome Therapeutics to Participate in Upcoming Investor Conferences

News > Science News

Audio By Carbonatix

7:00 AM on Thursday, February 26

The Associated Press

SAN DIEGO--(BUSINESS WIRE)--Feb 26, 2026--

Alterome Therapeutics, a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that members of its management team will participate in one-on-one investor meetings at the following upcoming conferences:

TD Cowen 46th Annual Health Care Conference, taking place March 2–4, 2026 in Boston, MA
Leerink Partners 2026 Global Healthcare Conference, taking place March 8–11, 2026 in Miami, FL

About Alterome Therapeutics

Alterome Therapeutics, Inc. is a clinical-stage precision oncology biotechnology company developing alteration-specific therapeutics to address high-value and validated oncogenic drivers. Our pipeline includes two Phase 1 therapies in development for solid tumors: ALTA2618, a first-in-class, oral mutation-selective inhibitor for AKT1 E17K-driven cancers, and ALTA3263, a first-in-class, oral pan-KRAS inhibitor designed to shut down KRAS activity in both ON and OFF states. Alterome has raised more than $231 million in venture capital to date and is led by a team of precision oncology R&D leaders with a history of successfully developing oncology small molecule drugs.

For more information, visit www.alterome.com and follow us on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260226754011/en/

CONTACT: Investors:

Scott Moorefield

Alterome Therapeutics

[email protected]

Media:

Michael Galfetti

Ten Bridge Communications

[email protected]

KEYWORD: CALIFORNIA MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH OTHER HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY